Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Nac De Sanidad AgropecuariafiledCriticalCt Nac De Sanidad Agropecuaria
Priority to CU1999187ApriorityCriticalpatent/CU22965A1/en
Publication of CU22965A1publicationCriticalpatent/CU22965A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicinal Preparation
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
El objeto de la presente invención es un procedimiento para la obtención de surfactante pulmonar natural. El surfactante se obtiene de la lixiviación de pulmones de cerdo triturados a través de un procedimiento de purificación sencillo, reproducible, escalable y económico. Su composición bioquímica se caracteriza por: más de 40% de fosfatidilcolina disaturada, más de un 12% de fosfolípidos aniónicos (fosfatidilinositol y fosfatidilglicerol), más de un 5%de triglicéridos, menos de un 2% de proteínas hidrófobas (SP-B y SP-C) y otros lípidos. Este medicamento tiene probada actividad tensoactiva y seguridad, sin necesidad de incorporar fosfolípidos sintéticos.The object of the present invention is a process for obtaining natural pulmonary surfactant. The surfactant is obtained from the leaching of crushed pork lungs through a simple, reproducible, scalable and economical purification procedure. Its biochemical composition is characterized by: more than 40% of desaturated phosphatidylcholine, more than 12% of anionic phospholipids (phosphatidylinositol and phosphatidylglycerol), more than 5% of triglycerides, less than 2% of hydrophobic proteins (SP-B and SP-C) and other lipids. This medicine has proven surfactant activity and safety, without the need to incorporate synthetic phospholipids.
CU1999187A1999-11-051999-11-05
PROCEDURE FOR OBTAINING PULMONARY SURFACTANT
CU22965A1
(en)
Compounds; process for the preparation of a compound; pharmaceutical composition; and method for the treatment and / or prophylaxis of diseases that are related to blood glucose level.
SEQUENCE OF SYNTHETIC NUCLEIC ACID CODIFYING AN ALPHA-GALACTOSIDASE, VECTOR AND CELL THAT UNDERSTAND IT, METHOD TO PRODUCE ALFA-GALACTOSIDASE, METHOD TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH PREPARATION FOR THIS PREPARATION AND SUITABILITY
Topological location and biological significance of phospholipids in the membrane of Newcastle disease virus. Hydrolysis of phospholipids in intact virion with pure phospholipases A2, C, and D